Gentium SpA, of Villa Guardia, Italy, filed the documentation requesting a re-examination of the negative opinion given by the European Committee for Medicinal Products for Human Use (CHMP), regarding the marketing authorization for defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy

SL-401 is a targeted therapy directed to the interleukin-3 receptor present on tumor bulk and cancer stem cells of multiple hematologic cancer indications

It provided new data showing efficacy of HemaXellerate for accelerating stem cell recovery after chemotherapeutic injury

The total grant of $729,000 yearly was awarded for development of BrainStorm's NurOwn autologous stem cells for amyotrophic lateral sclerosis

according to the protocol, all patients were to have been treated with both bortezomib and lenalidomide prior to study entry...Based on the positive results GSK said it is planning to make regulatory submissions in Europe, the U.S., as well as other regions during the next few

The total grant of $729,000 yearly was awarded for development of BrainStorm's NurOwn autologous stem cells for amyotrophic lateral sclerosis...Gentium SpA, of Villa Guardia, Italy, filed the documentation requesting a re-examination of the negative opinion given by the European Committee for Medicinal Products for Human Use (CHMP), regarding the marketing authorization for defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell

The trial, currently under way in Zurich, Switzerland, is designed to evaluate the safety and preliminary efficacy of its HuCNS-SC product candidate (purified human neural stem cells) as a treatment for chronic spinal cord injury

International Stem Cell Corp., of Carlsbad, Calif., said it started its investigational new drug application-enabling pharmacology and toxicology nonhuman primate studies...The studies will involve primates with moderate to severe Parkinson's disease symptoms and will assess the safety and functional efficacy of ISCO's stem cell-derived neuronal cells

Neuralstem Inc., of Rockville, Md., published results of a study of human neural stem cells (NSI-566) in rats with spinal cord injury showing improvement in several measures of motor function and a reduction of spasticity...The study was published in Stem Cell Research and Therapy

Sangamo BioSciences Inc., of Richmond, Calif., said the California Institute for Regenerative Medicine granted the firm a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP therapeutic for beta-thalassemia based on the application of its zinc finger nuclease gene-editing technology in hematopoietic stem cells

BioTime Inc., of Alameda, Calif., said at a special meeting on May 21, 2013, its shareholders approved the proposals related to the planned acquisition of stem cell-related assets from Geron Corp., of Menlo Park, Calif., by BioTime's subsidiary, Asterias Biotherapeutics Inc. (See BioWorld Today, April 5, 2013

GSK is developing a bone marrow-derived stem cell gene therapy through late phase development and has a small number of collaborations in that field

Stem Cell Therapeutics Corp., of Toronto, said the company's stock will trade on OTCQX International under the symbol "SCTPF" starting May 20

Pluristem Therapeutics Inc., of Haifa, Israel, identified a first clinical indication for its Placental eXpanded (PLX) RAD cells: to enhance engraftment of hematopoietic stem cells (HSCs) in patients experiencing delays or failure of their bone marrow transplants

VistaGen Therapeutics Inc., of South San Francisco, said its human pluripotent stem cell-derived cardiomyocytes were used by collaboration partner Duke University to grow three-dimensional (3D) human heart muscle...Duke researchers combined VistaGen's human stem cell-derived heart cells with tissue engineering and cardiac electrophysiology technologies to grow what they described as a "heart patch," which mimics the natural functions of native human heart tissue

BNC101 is designed to target cancer stem cells, with preclinical data demonstrating functional activity against LGR5

Sentien is developing an allogeneic cell therapy product consisting of bone marrow-derived mesenchymal stem cells seeded onto a medical device for critical care indications

Addex Therapeutics SA, of Geneva, reported preclinical data showing that its mGlu5 negative allosteric modulator oral small molecule, dipraglurant, dose-dependently prevented the abnormal excitatory effect observed on brain slices of transgenic primary generalized torsion dystonia 1 (DYT1) mice overexpressing the human mutant TOR1A gene by decreasing the paradoxical neuronal activity induced by the dopamine D2 receptor agonist quinpirole. DYT1 is a common and severe genetic form of dystonia

BNC101 is designed to target cancer stem cells, with preclinical data demonstrating functional activity against LGR5